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Background: Gastric non-Hodgkin’s lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists
about treatment. In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated
for a period of 20 years at a single institute.
Methods: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage I, 17
stage II, two stage III, and nine stage IV. The 46 stage I/II patients received aggressive, multimodal therapy: 24
of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery +
chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group
B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-
associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6). The 11 stage
III/IV patients received CT and/or RT with regimens similar to those for stage I/II patients.
Results: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination,
which proved that 42 had NHL. The rate of diagnostic accuracy by gastroscopy was 75%. After multimodal treatment
(n = 46) and a median follow-up of 54 months (range, 1–210 months), the 5-year survival rate was 40.3%. The
5-year survival rates for stage I, II and III/IV patients were 57.2%, 47% and 0%, respectively (p < 0.005). Of the
24 surgical patients (group A) who received sequential CT, with or without RT, 12 remained disease-free after a
median follow-up of 98 months (range, 1–210 months); three patients died because of postoperative complications.
Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free
after a median follow-up of 40 months (range, 4–189 months); one patient died because of massive gastric hemorrhage
after CT. All stage III and IV patients died after a median survival of 4 months (range, 1–8 months).
Conclusion: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL.
Surgery may still be necessary in cases of failed gastroscopic diagnosis. In early-stage gastric NHL, non-surgical
treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure. [J Chin
Med Assoc 2005;68(1):11–15]
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Introduction
The stomach is the most common site of primary ex-
tranodal non-Hodgkin’s lymphoma (NHL).1–3 Survi-
val associated with lymphoma at this site is better
than that for adenocarcinoma of the stomach,4–6 but
there are many controversial issues about the best
treatment, which is based on surgery, chemotherapy
(CT) and radiotherapy (RT).7,8 Traditionally, gas-
trectomy has been advocated as the first therapeutic
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step for patients with primary lymphoma of the
stomach.9–12 This was because of diagnostic accuracy
for large tumors and the ability to prevent life-
threatening complications of CT such as gastric
perforation and tumor bleeding.13,14 However, with
improved medical technology, diagnosis can be
achieved by direct gastroscopy.15,16 Recent treatment
has therefore focused mainly on CT, which can be
used instead of surgery in the early management of
gastric lymphoma.14,17
We carried out a retrospective review of our clinical
experience in the treatment of gastric lymphomas. We
aimed to compare the results of surgery-based or CT-
based treatment programs. Clinicopathologic features
of disease and overall survival were evaluated.
Methods
Fifty-seven patients with gastric NHL were treated at
Tri-Service General Hospital, Taipei, Taiwan, between
September 1984 and September 2003. All patients
initially presented with gastrointestinal symptoms and
then received direct gastroscopy or surgery, as clinically
indicated for diagnosis or treatment. Medical records
for these patients were retrospectively reviewed, inclu-
ding clinicopathologic characteristics, computed tomo-
graphy, surgical records, and follow-up information.
In all patients, a complete diagnostic evaluation was
performed, including blood-chemistry profile, chest
X-ray, and bone-marrow biopsy. Histologic classi-
fication was done according to World Health Organiza-
tion criteria18 and modified according to a recent
publication:19 low-grade B-cell lymphomas, comprising
marginal zone B-cell lymphoma of mucosa-associated
lymphoid tissue (MALT) type (MALT lymphoma),
follicular lymphoma, and mantle-cell lymphoma; high-
grade B-cell lymphoma, comprising diffuse, large
B-cell lymphoma (DLBL), Burkitt’s lymphoma, or
lymphoblastic lymphoma; and T-cell lymphoma.
Clinical stages were classified according to the Ann
Arbor staging system. Forty-six patients with stage
I and II NHL received an aggressive multimodal
treatment program (Table 1), and were divided into
group A (n = 24; mean age, 66 years) and group B
(n = 22; mean age, 62 years). Group A patients re-
ceived surgery-based management, which included
surgery alone (n = 6), surgery + CT (n = 14), surgery
+ RT (n = 2), and surgery + CT + RT (n = 2).
Gastrectomy was performed in 24 patients: subtotal
gastrectomy in 13, total gastrectomy in 3, and
radical total gastrectomy in 8. Group B patients did not
receive surgery, but received CT alone (n = 11), CT +
RT (n = 5), or, in patients with MALT lymphoma, an
oral anti-Helicobacter pylori regimen (n = 6). The
CHOP regimen was the principal CT protocol: cyclo-
phosphamide 500 mg/m2 on day 1, doxorubicin
50 mg/m2 on day 1, vincristine 1.4 mg/m2 (maximum
2 mg) on day 1, oral prednisolone 60 mg/m2 on days
1–5; a total of 6–8 cycles were administered at a
treatment interval of 21–28 days. For elderly patients
with other chronic conditions, the COP regimen of
cyclophosphamide, vincristine and prednisolone was
used. Patients with evidence of H. pylori-associated
MALT lymphoma received oral antibiotic treatment
with metronidazole, clarithromycin and omeprazole
for 10 days.
Eleven patients with stage III–IV disease received
RT, which was given as an abdominal bath with a total
dosage of 20–30 Gy (variable fractionation), and a
boost to the primary site. These patients received CT
and/or RT with regimens similar to those for stage I–
II patients.
Statistical analyses were performed using the
Statistical Package for the Social Sciences version
10.0 (SPSS Inc, Chicago, IL, USA). Survival time was
analyzed by the Kaplan-Meier method and calculated
from the time of primary diagnosis to the last follow-
up or death. Statistical significance was evaluated
by the log-rank test and indicated by a p value of
< 0.05.
Results
Clinical features
In the 57 patients with gastric NHL (37 males, 20
females), median age was 64 years (range, 14–83
years). Twenty-nine patients had stage I disease, 17
Table 1. Aggressive, multimodal treatment programs for 46
patients with stage I–II non-Hodgkin’s lymphoma
n (%)1
Surgery-based treatment 24 (52.2)
Surgery alone 16 (13.0)
Surgery + CT 14 (30.4)
Surgery + RT 2 (4.3)
Surgery + CT + RT 2 (4.3)
Non-surgical treatment 22 (47.8)
CT alone 11 (23.9)
CT + RT 15 (10.9)
Oral triple therapy for MALT lymphoma 16 (13.0)
CT = chemotherapy; RT = radiotherapy; MALT = mucosa-associated
lymphoid tissue.
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with ulceration (n = 11), adenocarcinoma (n = 2), and
leiomyoma (n = 1); biopsy was not performed in 1
patient. The rate of diagnostic accuracy by gastroscopy
was, therefore, 75%.
Treatment survival
After multimodal therapy (n = 46), the 5-year survival
rate after a median follow-up of 54 months (range, 1–
210 months) was 40.3%. Overall survival relating to
disease stages is illustrated in Figure 1. The 5-year
survival rates for stage I, II and III–IV patients were
57.2%, 47% and 0%, respectively (p < 0.005). All stage
III and IV patients died after a median survival of 4
months (range, 1–8 months).
Figure 2 compares the overall survival in surgical
(group A) and non-surgical (group B) patients; there
was no significant difference between the 2 groups
Table 2. Clinicopathologic characteristics in 57 patients
with gastric non-Hodgkin’s lymphoma
n (%) 1
Gender
Male 37 (65)11
Female 20 (35)11
Age (yr), median (range) 164 (14–83)
Stage
I 29 (50.9)
II 17 (29.8)
III 2 (3.5)
IV 19 (15.8)
Clinical symptom
Abdominal pain 36 (63.2)
Hematemesis 21 (36.8)
Poor appetite 17 (12.3)
Postprandial fullness 16 (10.5)
Vomiting 17 (12.3)
Weight loss 17 (12.3)
Diarrhea 2 (3.5)
Dysphagia 1 (1.8)
Dizziness 2 (3.5)
Dyspnea 2 (3.5)
Histologic subtype
Low-grade B-cell lymphoma 16 (28.1)
Marginal zone B-cell lymphoma of 14 (24.6)
   MALT type
Mantle-cell lymphoma 1 (1.8)
Follicular lymphoma 1 (1.8)
High-grade B-cell lymphoma 40 (70.2)
Diffuse large-cell lymphoma 35 (61.4)
Burkitt’s lymphoma 2 (3.5)
Lymphoblastic lymphoma 3 (5.3)
T-cell lymphoma 1 (1.8)
Result of gastric biopsy
Positive biopsy for lymphoma 42 (73.7)
Misdiagnosed as ulceration/gastritis 11 (19.3)
Misdiagnosed as adenocarcinoma 2 (3.5)
Misdiagnosed as leiomyoma 1 (1.8)
Biopsy not done 1 (1.8)
MALT = mucosa-associated lymphoid tissue.
stage II, 2 stage III, and 9 stage IV disease (Table 2).
The major symptoms were pain (63.2% of patients),
hematemesis (36.8%), and poor appetite (12.3%). The
most common pathologic subtype was diffuse, large-
cell lymphoma (61.4%).
Fifty-six patients underwent initial gastroscopy
because of their clinical symptoms; abnormal gastric
lesions were seen, and endoscopic tissue biopsies were
performed by experienced gastroenterologists. A
correct histologic diagnosis of NHL was made in 42
patients, whereas other patients were misdiagnosed
Figure 1. Kaplan-Meier analysis of overall survival relating to dis-
ease stage in 57 patients with gastric non-Hodgkin’s lymphoma.
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Figure 2. Overall survival in 46 patients with stage I/II gastric non-
Hodgkin’s lymphoma according to treatment: group A (n = 24)
patients received surgery-based treatment; group B (n = 22)
patients received non-surgical treatment.
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(p = 0.12). Twelve group A patients who received CT,
with or without RT, were disease-free after a median
follow-up of 98 months (range, 1–210 months). Twelve
patients died: 3 from postoperative complications;
1, a long-term survivor, from other causes (adeno-
carcinoma of the colon with liver metastasis) while
tumor-free at 98 months; and 8 from NHL relapse.
Fourteen group B patients who received CT, with or
without RT, were disease-free after a median follow-
up of 40 months (range, 4–189 months). Eight pa-
tients died: 1 from another cause (cirrhosis of the liver
with esophageal variceal bleeding); 1 from leukopenic
septic shock 5 months after starting CT; 1 from
massive gastric hemorrhage after CT; and 5 from
NHL relapse.
Discussion
Primary gastric NHL is a relatively uncommon gastric
neoplasm, which is reported to account for about 5%
of gastric malignancies.18,19 This series of 57 cases
comprises 3.1% of all gastric malignant neoplasms
seen at our hospital over a 20-year period.
The major presenting symptoms of gastric lym-
phoma were abdominal pain, fullness, hematemesis,
vomiting, and weight loss; these symptoms are similar
to those of benign or malignant gastric disorders.20
Hence, it is difficult to differentiate clinically between
gastric lymphoma and other gastric tumors. None-
theless, the typical picture of lymphoma seen at gas-
troscopy is a large lesion with extensive gastric wall
infiltration and ulceration, and a diagnostic accuracy
of up to 90% has been reported in some series.21,22
Gastroscopy was employed in 56 patients in this series,
but the diagnostic accuracy was only 75%. Factors
precluding diagnosis by endoscopic biopsy, because
they were difficult to interpret, were the lymphoma
growing deep into the submucosa, and large, ulcerat-
ing lesions exfoliating necrotic materials.23,24 Thus,
regardless of tumor appearance, multiple specimens
should be obtained by biopsy, particularly at the edges
of ulcerations. Repeated specimens should be taken at
the same site to reach the submucosa. Of course, non-
diagnostic or negative biopsies in patients with
radiologic or endoscopic evidence of gastric lesions
require further investigation with either repeat gas-
troscopy or surgical intervention.16,25
Total or partial gastrectomy was previously
considered the first, conventional-therapy step for
gastric NHL.9,24 The reasons for this approach were
as follows: exploration offering an opportunity to
diagnose; disease staging; potential removal of tumor
for good local control; and lack of CT or RT compli-
cations such as hemorrhage and perforation. However,
several studies have shown that improvements in the
diagnostic ability of gastroscopy have rendered surgery
both an inappropriate primary diagnostic tool and an
inappropriate initial treatment choice due to its high
operative mortality (up to 16–18%), and because
clinical responses and survival did not differ between
surgical and non-surgical patients.3,11 In our study, the
operative mortality rate was 12.5%, and overall survival
time did not differ significantly between surgery-based
and CT-based groups. Although nearly all authors
report that gastric resection should remove the risk
of bleeding and perforation from tumor necrosis that
may occur during CT and RT, such a risk was not seen
in our patients.
CT for high-grade gastric lymphoma is similar to
that for other high-grade NHL and is based mainly on
the CHOP regimen,14,17 which may be replaced by a
COP schedule in elderly patients or in those with poor
performance status, to prevent life-threatening com-
plications.4 The effects of other drug combinations
containing bleomycin, methotrexate and cytarabine
have also been reported in the literature.26 As we only
had a small number of patients who received RT, the
role of such therapy cannot be assessed from our data.
Further, RT has been used in only a few series, either
as an adjuvant to surgery or as a single treatment.
Nonetheless, RT is theoretically an additional effective
treatment for controlling local disease.15
The most important prognostic factors in gastric
lymphoma are clinical stage and cell type. All studies
have shown that limited disease carries a better prog-
nosis than extensive disease.5,13,23–26 However, the Ann
Arbor system is not suitable for the classification of
gastric lymphoma. Musshoff et al27 introduced a
modification for Ann Arbor stage II disease to differ-
entiate between local nodal involvement (II1) and
more distant spread to para-aortic nodes (II2). It is
reported that patients with stage II2 disease fare
significantly worse than those with stage II1 disease.27
Due to insufficient data, we could not analyze the
survival of stage II patients according to the Musshoff
staging system.
Based on our experience and data from the literature,
we believe that surgery should not be considered an
essential, primary treatment for gastric lymphoma.
Improvements in endoscopic technology, with accurate
diagnosis made from small biopsy specimens, led us
to eliminate gastrectomy as a necessary, initial proce-
dure.28 As there is survival benefit with CT-based treat-
ment, we recommend that initial CT should be manda-
tory in the treatment of gastric lymphoma.
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